Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
H7 BioCapital is a venture capital firm headquartered in Silicon Valley, established to focus on life science investments and business development within the pharmaceutical industry. Founded with the mission to advance healthcare innovation, H7 BioCapital invests in therapeutics and medtech while also running accelerator programs that support emerging companies in these fields.
The firm operates globally, with a particular emphasis on North America, Europe, and East Asia. H7 BioCapital has a diverse portfolio and engages in various stages of investment, from Friends & Family rounds to Pre-IPO financing. The firm is known for its strategic approach to investing, which includes utilizing Special Purpose Vehicles (SPVs) to facilitate funding for high-potential startups.
H7 BioCapital has made notable strides in the life sciences sector, including a significant exit with Arthrosi Therapeutics, a late-stage biotech company focused on gout treatment. This exit exemplifies the firm's commitment to identifying and nurturing companies with strong licensing and M&A potential.
H7 BioCapital primarily invests in the life sciences sector, targeting therapeutic companies in IND-enabling or clinical development stages, as well as medtech companies that are post-revenue or have clinical validation. The firm operates an angel syndicate that supports high-potential life science and medtech startups, providing funding and mentorship from seed to pre-IPO.
The investment strategy emphasizes companies with strong licensing and M&A potential, aligning with H7's thesis of investing from the demand side. For therapeutics, H7 seeks assets that demonstrate mechanistic rationale and translational evidence, while for medtech, the focus is on products that offer clear value for clinicians, patients, and payors. H7 BioCapital also runs a three-month healthcare accelerator program that provides educational support and resources to help startups navigate the complexities of the healthcare market.
H7 BioCapital's portfolio includes several notable companies that exemplify its focus on life sciences:
Ella Li, Ph.D. — Founding Partner at H7 BioCapital, Ella has a strong background in life-science venture investing and business development. She has been instrumental in shaping the firm's investment strategy and accelerator program.
Shu (Sophie) Lin, Ph.D. — Partner and Business Development Head at H7 BioCapital, Sophie emphasizes early business development planning. She has experience with over $300 million in upfront deals and potential milestones exceeding $4 billion, making her a key asset in identifying promising investment opportunities.
To pitch H7 BioCapital, founders should use the preferred channel of email at info@h7biocapital.com or submit through their website at h7biocapital.com/venture. The pitch deck should include a clear overview of the technology, market opportunity, and team qualifications. H7 BioCapital operates on a rolling application cycle, and while specific response times are not disclosed, founders can expect timely feedback on their submissions.
Warm introductions are beneficial but not mandatory. Founders should ensure their pitch clearly outlines the clinical validation and potential for licensing or M&A, as these are key factors in H7's investment decision-making process.
H7 BioCapital runs a healthcare accelerator program designed to support biotech, medtech, and device startups. This three-month program provides mentorship, funding, and educational resources to help startups navigate the complexities of the healthcare market. Eligible companies are typically in the seed to Series A stages and must demonstrate breakthrough healthcare technology.
Founders interested in applying to the accelerator can find more information on H7 BioCapital's website and are encouraged to submit their applications as part of the rolling application cycle.
In December 2025, H7 BioCapital participated in the financing round of Arthrosi Therapeutics, a late-stage biotech company focused on gout treatment. This investment preceded Sobi's acquisition agreement for up to $1.5 billion, marking a significant exit for H7 BioCapital.
Additionally, H7 BioCapital announced its 2024 accelerator cohort, which includes innovative companies such as Auctus Surgical, Limmi, and Cellentia. This cohort reflects the firm's commitment to supporting emerging startups in the life sciences sector.
What are H7 BioCapital's investment criteria?
H7 BioCapital invests in life sciences companies, particularly those in therapeutic IND-enabling or clinical development stages and medtech companies that are post-revenue or clinically validated. They look for strong licensing and M&A potential.
How can I pitch to H7 BioCapital?
Founders can pitch by visiting their website at h7biocapital.com/venture or by emailing info@h7biocapital.com. They accept pitches on a rolling basis.
What makes H7 BioCapital different from other investors?
H7 BioCapital focuses on life sciences investments with a strong emphasis on demand-side opportunities, targeting companies with potential for licensing and M&A. Their accelerator program also provides extensive mentorship and resources.
What is the geographic scope of H7 BioCapital's investments?
H7 BioCapital invests globally, with a focus on North America, Europe, and East Asia.
What is the typical check size for investments?
Specific check sizes are not disclosed, but H7 BioCapital invests across various stages, from seed to pre-IPO.
What kind of support do portfolio companies receive?
Portfolio companies benefit from H7 BioCapital's extensive network in the pharmaceutical and medtech industries, along with strategic guidance, mentorship, and access to funding opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.